PTPRC and neoplasm: Differences in the expression patterns of genes associated with CD45+, T cells (probes; CD2, CD3e, CD3g, CD6g), and tumor-associated macrophages (probes; CD68, CD163, CD84) showed that while single treatments were capable of increasing the levels of these cell types, most notable for CD45+ and T cells, over control (C44) levels, combination treatment further enhanced levels of these cell types compared with each single treatment (Fig. 6a).